tbuckley/cabot-search huggingface dataset:
Bioengineered omental transplant site promotes pancreatic islet allografts survival in non-human primates
Authors: Hongping Deng, Alexander Zhang, Dillon Ren Rong Pang, Yinsheng Xi, Zhihong Yang, Rudy Matheson, Guoping Li, Hao Luo, Kang M. Lee, Qiang Fu, Zhongliang Zou, Tao Chen, Zhenjuan Wang, Ivy A. Rosales, Cole W. Peters, Jibing Yang, María M. Coronel, Esma S. Yolcu, Haval Shirwan, Andrés J. García, James F. Markmann, Ji Lei
Journal: Cell Reports Medicine (2023)

The transplanting islets to the liver approach suffers from an immediate posttransplant loss of islets of more than 50%, progressive graft dysfunction over time, and precludes recovery of grafts should there be serious complications such as the development of teratomas with grafts that are stem cell-derived islets (SC-islets). The omentum features an attractive extrahepatic alternative site for clinical islet transplantation. We explore an approach in which allogeneic islets are transplanted onto the omentum, which is bioengineered with a plasma-thrombin biodegradable matrix in three diabetic non-human primates (NHPs). Within 1 week posttransplant, each transplanted NHP achieves normoglycemia and insulin independence and remains stable until termination of the experiment. Success was achieved in each case with islets recovered from a single NHP donor. Histology demonstrates robust revascularization and reinnervation of the graft. This preclinical study can inform the development of strategies for β cell replacement including the use of SC-islets or other types of novel cells in clinical settings.
Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity
Authors: Richard M. Ransohoff
Journal: Trends in Immunology (2023)

The emphasis on mechanisms driving multiple sclerosis (MS) symptomatic worsening suggests that we move beyond categorical clinical classifiers such as relapsing-remitting MS (RR-MS) and progressive MS (P-MS). Here, we focus on the clinical phenomenon progression independent of relapse activity (PIRA), which begins early in the disease course. PIRA occurs throughout MS, becoming more phenotypically evident as patients age. The underlying mechanisms for PIRA include chronic-active demyelinating lesions (CALs), subpial cortical demyelination, and nerve fiber injury following demyelination. We propose that much of the tissue injury associated with PIRA is driven by autonomous meningeal lymphoid aggregates, present before disease onset and unresponsive to current therapeutics. Recently, specialized magnetic resonance imaging (MRI) has identified and characterized CALs as paramagnetic rim lesions in humans, enabling novel radiographic-biomarker-clinical correlations to further understand and treat PIRA.
Oxygen-vacancy-rich molybdenum carbide MXene nanonetworks for ultrasound-triggered and capturing-enhanced sonocatalytic bacteria eradication
Authors: Lingqing Zong, Yang Yu, Junhao Wang, Peilai Liu, Wei Feng, Xinyue Dai, Liang Chen, Cindy Gunawan, Sung Lai Jimmy Yun, Rose Amal, Soshan Cheong, Zi Gu, Yu Chen
Journal: Biomaterials (2023)
Author Correction: Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains
Authors: Ditte Demontis, G. Bragi Walters, Georgios Athanasiadis, Raymond Walters, Karen Therrien, Trine Tollerup Nielsen, Leila Farajzadeh, Georgios Voloudakis, Jaroslav Bendl, Biau Zeng, Wen Zhang, Jakob Grove, Thomas D. Als, Jinjie Duan, F. Kyle Satterstrom, Jonas Bybjerg-Grauholm, Marie Bækved-Hansen, Olafur O. Gudmundsson, Sigurdur H. Magnusson, Gisli Baldursson, Katrin Davidsdottir, Gyda S. Haraldsdottir, Esben Agerbo, Gabriel E. Hoffman, Søren Dalsgaard, Jonna Martin, Marta Ribasés, Dorret I. Boomsma, Maria Soler Artigas, Nina Roth Mota, Daniel Howrigan, Sarah E. Medland, Tetyana Zayats, Veera M. Rajagopal, Alexandra Havdahl, Alysa Doyle, Andreas Reif, Anita Thapar, Bru Cormand, Calwing Liao, Christie Burton, Claiton H. D. Bau, Diego Luiz Rovaris, Edmund Sonuga-Barke, Elizabeth Corfield, Eugenio Horacio Grevet, Henrik Larsson, Ian R. Gizer, Irwin Waldman, Isabell Brikell, Jan Haavik, Jennifer Crosbie, James McGough, Jonna Kuntsi, Joseph Glessner, Kate Langley, Klaus-Peter Lesch, Luis Augusto Rohde, Mara H. Hutz, Marieke Klein, Mark Bellgrove, Martin Tesli, Michael C. O’Donovan, Ole Andreas Andreassen, Patrick W. L. Leung, Pedro M. Pan, Ridha Joober, Russel Schachar, Sandra Loo, Stephanie H. Witt, Ted Reichborn-Kjennerud, Tobias Banaschewski, Ziarih Hawi, Mark J. Daly, Ole Mors, Merete Nordentoft, Ole Mors, David M. Hougaard, Preben Bo Mortensen, Mark J. Daly, Stephen V. Faraone, Hreinn Stefansson, Panos Roussos, Barbara Franke, Thomas Werge, Benjamin M. Neale, Kari Stefansson, Anders D. Børglum
Journal: Nature Genetics (2023)
Author Correction: Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Authors: Barton F. Haynes, Kevin Wiehe, Persephone Borrow, Kevin O. Saunders, Bette Korber, Kshitij Wagh, Andrew J. McMichael, Garnett Kelsoe, Beatrice H. Hahn, Frederick Alt, George M. Shaw
Journal: Nature reviews. Immunology (2023)
m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion
Authors: Xiaoxue Cao, Qishun Geng, Danping Fan, Qiong Wang, Xing Wang, Mengxiao Zhang, Lu Zhao, Yi Jiao, Tingting Deng, Honglin Liu, Jing Zhou, Liqun Jia, Cheng Xiao
Journal: Molecular Cancer (2023)

Abstract N6-methyladenosine (m 6 A) methylation is the most universal internal modification in eukaryotic mRNA. With elaborate functions executed by m 6 A writers, erasers, and readers, m 6 A modulation is involved in myriad physiological and pathological processes. Extensive studies have demonstrated m 6 A modulation in diverse tumours, with effects on tumorigenesis, metastasis, and resistance. Recent evidence has revealed an emerging role of m 6 A modulation in tumour immunoregulation, and divergent m 6 A methylation patterns have been revealed in the tumour microenvironment. To depict the regulatory role of m 6 A methylation in the tumour immune microenvironment (TIME) and its effect on immune evasion, this review focuses on the TIME, which is characterized by hypoxia, metabolic reprogramming, acidity, and immunosuppression, and outlines the m 6 A-regulated TIME and immune evasion under divergent stimuli. Furthermore, m 6 A modulation patterns in anti-tumour immune cells are summarized.
Tumor-specific memory CD8+ T cells are strictly resident in draining lymph nodes during tumorigenesis
Authors: Qiao Liu, Ling Ran, Zhengliang Yue, Xingxing Su, Lisha Wang, Shuqiong Wen, Shun Lei, Xiaofan Yang, Yan Zhang, Jianjun Hu, Jianfang Tang, Zhirong Li, Li Hu, Bo Zhu, Lifan Xu, Lilin Ye, Qizhao Huang
Journal: Cellular and Molecular Immunology (2023)
LncRNA-BC069792 suppresses tumor progression by targeting KCNQ4 in breast cancer
Authors: Yunxiang Zhang, Xiaotong Dong, Xiangyu Guo, Chunsen Li, Yanping Fan, Pengju Liu, Dawei Yuan, Xialin Ma, Jingru Wang, Jie Zheng, Hongli Li, Peng Gao
Journal: Molecular Cancer (2023)

Abstract Background Breast cancer is the most common malignant tumor that threatens women's health. Attention has been paid on the study of long- non-coding RNA (lncRNA) in breast cancer. However, the specific mechanism remains not clear. Methods In this study, we explored the role of lncRNA BC069792 in breast cancer. In vitro and in vivo functional experiments were carried out in cell culture and mouse models. High-throughput next-generation sequencing technology and real-time fluorescence quantitative PCR technology were used to evaluate differentially expressed genes and mRNA expression, Western blot and immunohistochemical staining were used to detect protein expression. RNA immunoprecipitation assay and dual-luciferase activity assay were used to evaluate the competing endogenous RNAs (ceRNA), and rescue and mutation experiments were used for verification. Results We found that lncRNA BC069792 was expressed at a low level in breast cancer tissues, and significantly decreased in breast cancer with high pathological grade, lymph node metastasis and high Ki-67 index groups. Moreover, BC069792 inhibited the proliferation, invasion and metastasis of breast cancer cells in vitro and in vivo. Mechanically, BC069792 acts as a molecular sponge to adsorb hsa-miR-658 and hsa-miR-4739, to up-regulate the protein expression of Potassium Voltage-Gated Channel Q4 (KCNQ4), inhibits the activities of JAK2 and p-AKT, and plays a role in inhibiting breast cancer growth. Conclusions LncRNA BC069792 plays the role of tumor suppressor gene in breast cancer and is a new diagnostic index and therapeutic target in breast cancer.
Microfluidic‐Assisted Production of Gastro‐Resistant Active‐Targeted Diatomite Nanoparticles for the Local Release of Galunisertib in Metastatic Colorectal Cancer Cells (Adv. Healthcare Mater. 6/2023)
Authors: Chiara Tramontano, João Pedro Martins, Luca De Stefano, Marianna Kemell, Alexandra Correia, Monica Terracciano, Nicola Borbone, Ilaria Rea, Hélder A. Santos
Journal: Advanced Healthcare Materials (2023)

Nanoparticle Drug Delivery The encapsulation of nanoparticles in hydroxypropyl methyl cellulose is key to treat colorectal cancer through oral administration. In article 2202672 by Ilaria Rea, Hélder A. Santos, and co-workers, gelatin-coated diatomite nanoparticles loaded with galunisertib are functionalized with an anti-L1-CAM antibody that targets metastatic colon cancer cells. These nanoparticles are then encapsulated in a gastro-resistant matrix using microfluidics. When the nanoparticles interact with the targeted cells, the gastro-resistant coating dissolves and galunisertib is released.
Reactive Oxygen Species‐Triggered Hydrogen Sulfide Release and Cancer‐Selective Antiproliferative Effect of Anethole Dithiolethione‐Containing Polymeric Micelles (Adv. Healthcare Mater. 6/2023)
Authors: André J. van der Vlies, Masoud Ghasemi, Bernadette M. Adair, James H. Adair, Enrique D. Gomez, Urara Hasegawa
Journal: Advanced Healthcare Materials (2023)

Polymeric Micelles In article 2201836 by Urara Hasegawa and co-workers, polymeric micelles containing H2S-donating anethole dithiolone (ADT) groups release H2S in response to oxidation by reactive oxygen species (ROS). By changing polymer design, H2S release profiles can be fine-tuned to suppress cancer cell proliferation in human colon cancer in vitro assays, as well as a chick chorioallantois membrane cancer model.
Nanodroplet‐Coated Microbubbles Used in Sonothrombolysis with Two‐Step Cavitation Strategy (Adv. Healthcare Mater. 6/2023)
Authors: Yunfan Pan, Yongjian Li, Yan Li, Xiaobing Zheng, Chenghong Zou, Jiang Li, Haosheng Chen
Journal: Advanced Healthcare Materials (2023)

Microbubbles In article 2202281 by Jiang Li, Haosheng Chen, and co-workers, nanodroplet-coated microbubbles (NCMBs) are designed to realize a two-step cavitation strategy to accelerate thrombolysis. The first cavitation drives nanodroplets into the thrombus, while the second cavitation loosens the thrombus. NCMBs can be used as a promising medicines carrier with rapid diffusion and help with the design of efficient drug delivery systems.
The double-edged sword of PCOS and gender: exploring gender-diverse experiences of polycystic ovary syndrome
Authors: Katrina Wugalter, Mateja Perovic, Laurice Karkaby, Gillian Einstein
Journal: International Journal of Transgender Health (2023)

AbstractAbstractBackground: Past research on polycystic ovary syndrome (PCOS), a chronic endocrine condition, has focused on the experiences of cisgender women.Aims: The purpose of the present study was to address the knowledge gap about gender-diverse individuals by exploring their lived experiences with PCOS and to better understand if and how their gender identity affected their experience of PCOS.Methods: To explore this, we recruited nine non-binary people and one transgender man with a PCOS diagnosis for qualitative interviews.Results: Three overarching themes emerged: PCOS as a burden, PCOS as an occasion, and PCOS as a benefit. While some aspects of PCOS created an additional burden for our participants, other symptoms such as excess body and facial hair could be empowering and affirming, revealing a positive aspect of this chronic condition.Conclusion: This study is the first to describe the lived experiences of gender-diverse individuals with PCOS, uncovering burdens as well as some benefits. Future research in this population may reveal not only the particulars of what PCOS is like for them but also more generalizable insights into the highly gendered perception and treatment of PCOS.Keywords: Gender identitynon-binarypolycystic ovary syndromequalitative researchtransgender AcknowledgmentsWe thank the participants for their contributions to this project. We acknowledge the work of our volunteer, Julia Mallen, in transcribing interviews.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments of comparable ethical standards.Conflict of interestThe authors declare that they have no conflicts of interest.Declaration of interest statementThe authors declare that they have no conflicts of interest.Additional informationFundingThis work was supported by the Jacqueline Ford Gender and Health Fund (to G. Einstein); and Wilfred and Joyce Posluns Chair in Women's Brain Health and Aging from the Poslun Family Foundation, Canadian Institutes of Health Research, Alzheimer's Society of Canada, and Ontario Brain Institute under Grant WJP-150643 (to G. Einstein).
Selected Articles from This Issue
Journal: Clinical Cancer Research (2023)

Elía and colleagues propose that progesterone receptor (PR) ligands may serve as therapeutic tools for luminal breast cancer.Preclinical data suggest that antiprogestins inhibit tumor growth and metastasis in breast cancer models with higher levels of PR isoform A (PRA) than isoform B (PRA-H tumors), while they stimulate the metastatic burden in those with the opposite ratio.The MIPRA trial showed that mifepristone neoadjuvant treatment benefits patients with PRAH tumors and underscores the relevance of testing the PR isoform ratio before administering antiprogestins to patients with breast cancer.Proteomics, coupled with RNA-Seq profiling, revealed mifepristone-modulated biological processes that explain and strengthen the Ki67 data.The fact that lymph node metastases retain the PRA/PRB ratio as the primary tumor posits this subgroup of patients as recipients of antiprogestin treatment, even in adjuvant settings.These findings suggest that mifepristone may be included in the armamentarium against breast cancer in the future.
A Versatile Continuum Gripping Robot with a Concealable Gripper
Authors: Shuailong Zhang, Fenggang Li, Rongxin Fu, Hang Li, Suli Zou, Nan Ma, Shengyuan Qu, Jian Li
Journal: Cyborg and Bionic Systems (2023)

Continuum robots with their inherent compliance provide the potential for crossing narrow unstructured workspace and safely grasping various objects. However, the display gripper increases the size of the robots, and therefore, it tends to get stuck in constrained environments. This paper proposes a versatile continuum grasping robot (CGR) with a concealable gripper. The CGR can capture large objects with respect to the robot's scale using the continuum manipulator and can grasp various objects using the end concealable gripper especially in narrow and unstructured workspaces. To perform the cooperative operation of the concealable gripper and the continuum manipulator, a global kinematic model based on screw theory and a motion planning approach referred to as "multi-node synergy method" for the CGR are presented. The simulation and experimental results show that objects of different shapes and sizes can be captured by the same CGR even in complex and narrow environments. Finally, in the future, the CGR is expected to serve for satellite capture in harsh space environments such as high vacuum, strong radiation, and extreme temperatures.
Bladder microenvironment actuated proteomotors with ammonia amplification for enhanced cancer treatment
Authors: Hao Tian, Juanfeng Ou, Yong Wang, Jia Sun, Junbin Gao, Yicheng Ye, Ruotian Zhang, Bin Chen, Fei Wang, Weichang Huang, Huaan Li, Lu Liu, Chuxiao Shao, Zhili Xu, Fei Peng, Yingfeng Tu
Journal: Acta Pharmaceutica Sinica B (2023)

Enzyme-driven micro/nanomotors consuming in situ chemical fuels have attracted lots of attention for biomedical applications. However, motor systems composed by organism-derived organics that maximize the therapeutic efficacy of enzymatic products remain challenging. Herein, swimming proteomotors based on biocompatible urease and human serum albumin are constructed for enhanced antitumor therapy via active motion and ammonia amplification. By decomposing urea into carbon dioxide and ammonia, the designed proteomotors are endowed with self-propulsive capability, which leads to improved internalization and enhanced penetration in vitro. As a glutamine synthetase inhibitor, the loaded l-methionine sulfoximine further prevents the conversion of toxic ammonia into non-toxic glutamine in both tumor and stromal cells, resulting in local ammonia amplification. After intravesical instillation, the proteomotors achieve longer bladder retention and thus significantly inhibit the growth of orthotopic bladder tumor in vivo without adverse effects. We envision that the as-developed swimming proteomotors with amplification of the product toxicity may be a potential platform for active cancer treatment.
Corrigendum to: “Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)” Clinical Microbiology and Infection 26 (2020) 1545–1553
Authors: Michele Bartoletti, Maddalena Giannella, Luigia Scudeller, Sara Tedeschi, Matteo Rinaldi, Linda Bussini, Giacomo Fornaro, Renato Pascale, Livia Pancaldi, Zeno Pasquini, Filippo Trapani, Lorenzo Badia, Caterina Campoli, Marina Tadolini, Luciano Attard, Massimo Puoti, Marco Merli, Cristina Mussini, Marianna Menozzi, Marianna Meschiari, Mauro Codeluppi, Francesco Barchiesi, Francesco Cristini, Annalisa Saracino, Alberto Licci, Silvia Rapuano, Tommaso Tonetti, Paolo Gaibani, Vito M. Ranieri, Pierluigi Viale
Journal: Clinical Microbiology and Infection (2023)
Upstream and downstream regulators of Klotho expression in chronic kidney disease
Authors: Sha-Sha Li, Ming-Jie Sheng, Zhuo-Yi Sun, Yan Liang, Li-Xia Yu, Qi-Feng Liu
Journal: Metabolism (2023)

Klotho is a critical protein that protects the kidney. Klotho is severely downregulated in chronic kidney disease (CKD), and its deficiency is implicated in the pathogenesis and progression of CKD. Conversely, an increase in Klotho levels results in improved kidney function and delays CKD progression, supporting the notion that modulating Klotho levels could represent a possible therapeutic strategy for CKD treatment. Nevertheless, the regulatory mechanisms responsible for the loss of Klotho remain elusive. Previous studies have demonstrated that oxidative stress, inflammation, and epigenetic modifications can modulate Klotho levels. These mechanisms result in a decrease in Klotho mRNA transcript levels and reduced translation, thus can be grouped together as upstream regulatory mechanisms. However, therapeutic strategies that aim to rescue Klotho levels by targeting these upstream mechanisms do not always result in increased Klotho, indicating the involvement of other regulatory mechanisms. Emerging evidence has shown that endoplasmic reticulum (ER) stress, the unfolded protein response, and ER-associated degradation also affect the modification, translocation, and degradation of Klotho, and thus are proposed to be downstream regulatory mechanisms. Here, we discuss the current understanding of upstream and downstream regulatory mechanisms of Klotho and examine potential therapeutic strategies to upregulate Klotho expression for CKD treatment.
The effects of obesity and metabolic abnormalities on severe COVID-19-related outcomes after vaccination: A population-based study
Authors: Xiude Fan, Junming Han, Enfa Zhao, Jiansong Fang, Dawei Wang, Yiping Cheng, Yingzhou Shi, Zhen Wang, Zhenyu Yao, Peng Lu, Tianbao Liu, Qihang Li, Kyle L. Poulsen, Zhongshang Yuan, Yongfeng Song, Jiajun Zhao
Journal: Cell Metabolism (2023)
The decrease in plasma cholesterol during Plasmodium falciparum infections is not caused by cholesterol utilization by the parasites but by an infection-induced acute-phase response
Authors: Klaske J. Vliegenthart-Jongbloed, Rob Koelewijn, Aloysius G.M. Tielens, Robert W. Sauerwein, Jaap J. van Hellemond, Perry J.J. van Genderen
Journal: Journal of Infection (2023)
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
Authors: Ayechew Adera Getu, Abiye Tigabu, Ming Zhou, Jianrong Lu, Øystein Fodstad, Ming Tan
Journal: Molecular Cancer (2023)

B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer progression. This immune checkpoint molecule is selectively expressed in both tumor cells and immune cells within the tumor microenvironment. In addition to its immune checkpoint function, B7-H3 has been linked to tumor cell proliferation, metastasis, and therapeutic resistance. Furthermore, its drastic difference in protein expression levels between normal and tumor tissues suggests that targeting B7-H3 with drugs would lead to cancer-specific toxicity, minimizing harm to healthy cells. These properties make B7-H3 a promising target for cancer therapy.Recently, important advances in B7-H3 research and drug development have been reported, and these new findings, including its involvement in cellular metabolic reprograming, cancer stem cell enrichment, senescence and obesity, have expanded our knowledge and understanding of this molecule, which is important in guiding future strategies for targeting B7-H3. In this review, we briefly discuss the biology and function of B7-H3 in cancer development. We emphasize more on the latest findings and their underlying mechanisms to reflect the new advances in B7-H3 research. In addition, we discuss the new improvements of B-H3 inhibitors in cancer drug development.
WHO's pandemic treaty: promises of equity should be kept
Authors: None The Lancet Global Health
Journal: The Lancet Global Health (2023)

The global response to COVID-19 was a failure. As of Feb 21, 2023, there have been more than 750 million cases and 6·8 million deaths attributed to COVID-19. Nations once thought of as well prepared for pandemics, such as the USA and UK, have suffered hundreds of thousands of excess deaths. When the next pandemic comes, the world must do better. And the WHO accord on pandemic prevention, preparedness and response (WHO CA+) is our first inclination of what better could look like.